Search titles and summaries
Population match Any Direct match Partial match Different population Not human evidence Population unclear
Topic Any Inflammation Cardiovascular Cerebrovascular Kidney Cognition Dementia Alzheimers Parkinsons Neuroinflammation Osteoarthritis Rheumatologic Muscle Lean mass Body composition Bone Liver Immune Cancer Addiction Sleep Aging Mortality Metabolic Adverse effects Nutrition Endocrine Gastrointestinal Psychiatric Ophthalmologic Perioperative Discontinuation Other emerging
Drug Any Semaglutide Liraglutide Dulaglutide Exenatide Lixisenatide Efpeglenatide Tirzepatide Retatrutide Survodutide Mazdutide Orforglipron Cagrisema Class unspecified
Design Any Randomized trial Crossover trial Clinical trial Prospective cohort Retrospective cohort Case-control Mendelian randomization Systematic review Meta-analysis Umbrella review Pharmacovigilance Case series Case report Animal study Cell / in-vitro Mechanistic review Narrative review Guideline Editorial Regulatory document Trial registration Modelling study Design unknown
Study tier Any Study tier 1 Study tier 2 Study tier 3 Study tier 4 Preliminary Not rated
Outcome type Any Hard Intermediate Biomarker Surrogate Mixed Unknown
Direction Any Benefit Harm Null Mixed Unclear
Explained by weight loss? Any Likely Possibly Unlikely Specifically tested Unknown Not applicable
Industry funded Any Yes Partial No Unclear
Peer reviewed Any Yes No
Published from year
